Literature DB >> 11128057

Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of functional and quality of life scales.

L Demers1, M Oremus, A Perrault, N Champoux, C Wolfson.   

Abstract

The psychometric properties of functional and quality of life outcome measures that were used for the purpose of showing changes in antidementia drug trials for Alzheimer's disease are described and critiqued. The seven functional scales reviewed for reliability, validity, and responsiveness to change included the Geriatric Evaluation by Relative's Rating Instrument, the Physical Self-Maintenance Scale, the Instrumental Activities of Daily Living, the Blessed Dementia Scale, Part 1 and its revised version, the Interview for Deterioration in Daily Living with Dementia, the Unified Activities of Daily Living, and the Dependence Scale. The Progressive Deterioration Scale and Quality of Life Assessment were classified as quality of life scales. The majority of the scales were found to exhibit serious limitations, such as incomplete reliability and validity assessment for the intended uses. The most pervasive problem was a lack of data on responsiveness to change. It is recommended that further research be conducted to develop new tools or enhance existing measures for the assessment of both quality of life and functional ability.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11128057     DOI: 10.1177/089198870001300402

Source DB:  PubMed          Journal:  J Geriatr Psychiatry Neurol        ISSN: 0891-9887            Impact factor:   2.680


  8 in total

1.  Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Authors:  Martin R Farlow; Stephen Salloway; Pierre N Tariot; Jane Yardley; Margaret L Moline; Qin Wang; Elimor Brand-Schieber; Heng Zou; Timothy Hsu; Andrew Satlin
Journal:  Clin Ther       Date:  2010-07       Impact factor: 3.393

2.  The independent contributions of cognitive impairment and neuropsychiatric symptoms to everyday function in older adults.

Authors:  Lauren A Rog; Lovingly Quitania Park; Danielle J Harvey; Chun-Jung Huang; Scott Mackin; Sarah Tomaszewski Farias
Journal:  Clin Neuropsychol       Date:  2014-02-06       Impact factor: 3.535

Review 3.  Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment.

Authors:  Abhilash K Desai; George T Grossberg; Dharmesh N Sheth
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

4.  Everyday cognition in prodromal Huntington disease.

Authors:  Janet K Williams; Ji-In Kim; Nancy Downing; Sarah Farias; Deborah L Harrington; Jeffrey D Long; James A Mills; Jane S Paulsen
Journal:  Neuropsychology       Date:  2014-07-07       Impact factor: 3.295

5.  The validity of dependence as a health outcome measure in Alzheimer's disease.

Authors:  D Eldon Spackman; Srikanth Kadiyala; Peter J Neumann; David L Veenstra; Sean D Sullivan
Journal:  Am J Alzheimers Dis Other Demen       Date:  2013-03-19       Impact factor: 2.035

6.  Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease.

Authors:  Lori Frank; William R Lenderking; Kellee Howard; Marc Cantillon
Journal:  Alzheimers Res Ther       Date:  2011-12-09       Impact factor: 6.982

Review 7.  Quality of Life measures for dementia.

Authors:  Rebecca E Ready; Brian R Ott
Journal:  Health Qual Life Outcomes       Date:  2003-04-23       Impact factor: 3.186

8.  Variability in the validity and reliability of outcome measures identified in a systematic review to assess treatment efficacy of cognitive enhancers for Alzheimer's Dementia.

Authors:  Charlene Soobiah; Mina Tadrous; Sandra Knowles; Erik Blondal; Huda M Ashoor; Marco Ghassemi; Paul A Khan; Joanne Ho; Andrea C Tricco; Sharon E Straus
Journal:  PLoS One       Date:  2019-04-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.